ClinicalTrials.gg
Status unknownNCT02757560Updated Aug 1, 2019

Dietary Lipid Induced Insulin Resistance

An interventional study of SFA diet and MUFA diet in Insulin Resistance, sponsored by Phoenix VA Health Care System. Status unknown at 1 site in United States. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-01.

Sponsored by Phoenix VA Health Care System · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jul 2019), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

The overall goal of the proposal is to use a saturated fatty acid (SFA)- enriched, high fat diet to rapidly induce insulin resistance (IR) to provide insight into underlying proximal mechanisms of reduced insulin signaling. Specifically, investigators will identify the initial changes in metabolite concentrations/or pathway signaling ("pathways" will be used to broadly refer to these mechanism specific measures) and therefore the mechanisms most likely responsible for the development of IR during this high fat nutritional challenge. Investigators have assembled a multidisciplinary team that is versed with dietary studies, fatty acid metabolism, measurement of IR and potential mechanisms and mediators of IR, and has experience working with monocytes and the two tissues, muscle and adipose tissue, that are particularly relevant for understanding the effects of high fat diets on IR.

Read the detailed description

In the first aim, investigators will test whether a short-term high SFA-diet induces and increases insulin resistance in participants with normal and abnormal glucose tolerance, respectively, and determine the associated changes in muscle, adipose tissue and inflammatory cell composition, pathway activation and insulin signaling. Investigators will identify changes in specific signal pathways within these tissues and cells that are hypothesized to mediate or modulate insulin action. Primary mechanisms and pathways examined will include local tissue and systemic inflammation, formation of bioactive lipid intermediates, generation of endoplasmic reticulum (ER) stress, and mitochondrial dysfunction/reactive oxygen formation. By performing studies in participants with normal glucose tolerance and in those with abnormal glucose tolerance investigators will also determine whether the extent and mechanisms of insulin resistance vary with initial degrees of glucose intolerance.

In the second aim, to determine if the extent and mechanisms of insulin resistance vary with dietary composition, investigators will determine whether diets of similar caloric content as the SFA-diet, but enriched in monounsaturated fatty acids or carbohydrates, also induce insulin resistance and whether similar or different mechanistic pathways are responsible. Identifying similarities and differences between diets in inflammatory cell and tissue changes and comparing their relationships with peripheral and tissue insulin action will further clarify which cell and tissue events are most closely linked to development of insulin resistance.

In the final aim, to identify the temporal sequence of mechanistic pathways for insulin resistance and the role of cell and tissue cross-talk in these events, investigators will evaluate inflammatory cell, skeletal muscle and adipose tissue composition and pathway changes after acute, subacute, and more chronic dietary challenges in the same individuals. This will also permit assessment of whether repeated dietary challenges create changes in tissues that resemble those found in more chronic and advanced states of insulin resistance.

02

Conditions studied

  • Insulin Resistance

Browse trials for

Keywords

  • saturated fat
  • acute insulin resistance
  • insulin suppression test
  • dietary fatty acids
03

In context

Insulin Resistance

2,969 studies on the registry are indexed under Insulin Resistance; 338 are open to participants now.

This study's planned enrollment of 300 is above the median of 40 across 2,369 interventional studies indexed under Insulin Resistance.

Browse Insulin Resistance studies →

Lead sponsor

Phoenix VA Health Care System is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) from 25-35 kg/m2
  • normal glucose tolerance (NGT) diagnosis based on fasting glucose value 100mg/dl and 2 hr glucose \<140 mg/dl after a standard 75 gm glucose load; impaired fasting glucose (IFG) on fasting glucose value ≥100 and \<126 mg/dl and 2 hr glucose \<140 mg/dl; impaired glucose tolerance (IGT) based on 2 hr glucose ≥140 and \<200 mg/dl and a fasting glucose \<126 mg/dl
  • Fasting triglyceride levels \<500 mg/dl

Exclusion criteria

Exclusion Criteria:

  • Type 1 or 2 diabetes mellitus or a value ≥ 6.5 mg/dl
  • Any diabetes medications in the past month, thiazolidinedione medications in the prior 3 months or prior regular use of insulin
  • Use of diets, medications (e.g., , weight loss medications ) or current or planned behavior changes (e.g. acute weight loss, exercise training) that will influence changes in IR
  • Creatinine >2.0 mg/dl or other laboratory evidence of significant active disease, including hepatic enzyme elevation >2x normal and anemia, known "Nonalcoholic Fatty Liver Disease", bleeding risk
  • Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems, or recent history of nausea or vomiting
  • Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks
  • Cardiovascular event, stable or unstable angina or other major illness in the past 6 months
  • Current regular use of anti-inflammatory medications (e.g. salicylates > 1 gm/ day) or antioxidants in excess of a daily multi-vitamin, including supplements (e.g. fish oils)
  • Lipid lowering medications must be at a stable dose for at least 2 months prior to participation
  • Ethanol consumption more than 4 oz day; more than occasional smoker
  • Reproductively active women not on
  • Known allergies, prior reactions or to proposed clinical agents (e.g Octreotide)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    SFA versus control diet

    Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour saturated fatty acids enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the SFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (SFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).

    Other: SFA diet

  • Experimental
    MUFA versus control diet

    Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour monounsaturated fatty acids (MUFA) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the MUFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (MUFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).

    Other: MUFA diet

  • Experimental
    CARB versus control diet

    Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).

    Other: CARB diet

Interventions

  • OtherSFA diet

    SFA versus control diet

  • OtherMUFA diet

    MUFA versus control diet

  • OtherCARB diet

    CARB versus control diet

06

What researchers measure

Primary outcomes

  1. Steady-state plasma glucose (SSPG)

    Average plasma glucose concentrations during min 150-180 of the insulin suppression test (IST)

    Time frame: 150-180 min

Secondary outcomes

  1. Acylcarnitine species

    Measured by chromatography electrospray ionization mass spectrometry on plasma and skeletal muscle samples.

    Time frame: Overnight fast, 3-hour post breakfast

  2. Diacylglycerol species

    Measured on plasma, skeletal muscle and subcutaneous adipose tissue samples.

    Time frame: Overnight fast, 3-hour post breakfast

  3. Ceramides species

    Measured on plasma, skeletal muscle and subcutaneous adipose tissue samples.

    Time frame: Overnight fast, 3-hour post breakfast

  4. Insulin signaling proteins

    Measured on skeletal muscle and subcutaneous adipose tissue samples.

    Time frame: Overnight fast, 3-hour post breakfast

  5. Inflammation markers

    Cytokines and adipokines will be measured in plasma after the diet treatments by ELISA techniques. Mononuclear cells inflammatory gene expression will be measured by real time polymerase chain reaction (RT-PCR). Inflammation will be measured in muscle and adipose tissue by RT-PCR and Western blood analysis.

    Time frame: Overnight fast, 3-hour post breakfast

07

Study locations

1 site
  • Carl T. Hayden VA Medical Center
    Phoenix, Arizona 85012, United States
08

References and documents

Individual participant data

Plan to share: No — Subject to VA regulation.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jul 2020 and a completion of Dec 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2015
First posted
May 2, 2016
Start
Feb 2012
Primary completionEst.
Jul 2020
CompletionEst.
Dec 2020
Last update
Aug 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02757560
Lead sponsor
Phoenix VA Health Care System
Responsible party
Sponsor
First posted
May 2, 2016
Start date
Feb 2012
Primary completion
Jul 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Aug 1, 2019

Study contacts

Peter D Reaven, MD
principal investigator · Phoenix Veterans Affairs Health Care System

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion